Zymar, Zymaxid Antitrust Direct Purchaser Class Action Settlement

Class Eligibility

All persons or entities in the United States who purchased branded Zymar or Zymaxid directly from any of the Defendants from and including June 15, 2010 through December 31, 2017.

Estimated Amount


Proof of Purchase


Case Name

Hartig v. Senju, et al.,
Case No. 1:14-­cv­-00719,

District Court for the District of Delaware

Case Summary

The lawsuit alleges that Defendants engaged in an unlawful scheme to eliminate or delay generic competition for gatifloxacin ophthalmic solution (generic versions of their branded drugs Zymar and Zymaxid), a drug used to treat eye infections such as bacterial conjunctivitis, in violation of the Sherman Act. Defendants have denied any liability for these claims and have asserted various defenses to the claims.

Settlement Pool





Hartig Drug Company Inc. v. Senju Pharmaceutical Co. Ltd. Settlement

c/o GCG

PO Box 9349

Dublin, OH 43017-4249